Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
IPO Year: 2011
Exchange: NASDAQ
Website: lumos-pharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 7/21/2021 | $34.00 → $27.00 | Buy | HC Wainwright & Co. |
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. "The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201's pulsatile
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin,
AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the "Merger Agreement") whereby Double Point Ventures LLC ("DPV") will acquire 100% of Lumos Pharma's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right ("CVR") per share payable on achievement of certain milestones (the "Offer"). Following a thorough review of financing and strategic alternatives, Lumos Pharma's
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zeal
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile. Abstract Presentation: Friday, September 13th – E-poster Session 2 – 1:15-2:30PM Local Time Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in M
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th Title:Lumos Pharma Corporate Presentation (On-Demand) Date/Time:September 9th at 7:00AM EDT Webcast Link:Register here 1x1 Meetings:Monday-Tuesday, September 9th-10th The p
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024. "The new analyses of data from our OraGrowtH212 Trial further characterized LUM-201's unique ability to augment the natural pulsatile secretion of growth hormone, producing comparable growth to injectable rhGH with significantly less exposure
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024. Poster Session P069 – Monday June 3, 12:00-1:30 PM ET Poster MON-111 : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD): Key Discoveries from Phase 2 of OraGrowtH212 Trial (Fernando Cassor
SC 14D9 - LUMOS PHARMA, INC. (0001126234) (Subject)
10-Q - LUMOS PHARMA, INC. (0001126234) (Filer)
SCHEDULE 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC14D9C - LUMOS PHARMA, INC. (0001126234) (Subject)
8-K - LUMOS PHARMA, INC. (0001126234) (Filer)
10-Q - LUMOS PHARMA, INC. (0001126234) (Filer)
8-K - LUMOS PHARMA, INC. (0001126234) (Filer)
8-K - LUMOS PHARMA, INC. (0001126234) (Filer)
8-K - LUMOS PHARMA, INC. (0001126234) (Filer)
10-K/A - LUMOS PHARMA, INC. (0001126234) (Filer)
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, today announced the outcome from its End-of-Phase 2 meeting with the FDA, provided a clinical programs update, and reported financial results for the quarter ended March 31
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Wednesday, May 15, 2024Time: 8:30am ETDial-in: 1-877-407-9716 or 1-201-493-6779 (International)Conference ID: 13746447Dial-in registration (Ava
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit "Duke" Pitukcheewanont, MD, Appointed Chief Medical Officer Conference Call Today at 4:30 PM EST AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), today announced financial results for the year ended December 31, 2023 and provided an update on clinical and r
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click
-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent with Historical Growth Rates for Moderate PGHD Population – -- OraGrowtH212 Data Confirm Unique Pulsatile Mechanism of Action of LUM-201and Demonstrate Closer to Normal Physiological Growth Hormone Levels and Normalized IGF-1 Levels – -- Cash of $42.7 Million at End of Q3 2023 Provides Runway through Third Quarter 2024 -- AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Ph
OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD PopulationDelta at 6 and 12-month AHV Between Optimal LUM-201 Dose of 1.6 mg/kg and rhGH Comparator Arm is Within the Non-inferiority Margin (< 2 cm/yr) Suggested by FDA for Recent ApprovalsInitial 24-month LUM-201 Data from Combined OraGrowtH210 and OraGrowtH212 Trials Demonstrate a Sustained AHV Effect from Year 1 to Year 2Met Pre-specified Primary Endpoint of Validation of Predictive Enrichment Marker (PEM) Test and Secondary Endpoint Demonstrating 100% Reproducibility of PEM-Positive Classificatio
Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023Encouraging Interim Data from OraGrowtH Trials Presented at ENDO 2023, Highlighted in KOL WebinarConference Call Scheduled for Today at 4:30pm ET AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the second quarter ended June 30, 2023. "We are pleased to confirm our expectation for primary data readout from our two P
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please c
HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $27.00 from $34.00 previously
Stifel upgraded Lumos Pharma from Hold to Buy and set a new price target of $24.00 from $4.00 previously
Stifel Nicolaus upgraded Lumos Pharma from Hold to Buy
SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13D/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13D/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13D/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13D/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13D/A - LUMOS PHARMA, INC. (0001126234) (Subject)
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18) by 9.32 percent. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $302.60 thousand by 45.47 percent. This is a 76.12 percent decrease over sales of $691.00 thousand the same period last year.
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.
Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and maintains $16 price target.
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.
Lumos Pharma (NASDAQ:LUMO) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Lumos Pharma missed estimated earnings by -2.0%, reporting an EPS of $-1.17 versus an estimate of $-1.15. Revenue was up $314 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.11 which was followed by a 11.0% increase in the share price the next day. Here's a look at Lumos Pharma's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -1.15 -1.10 -1.12 -0.93 EPS Actual -1.04 -1.09 -0.89 -0.98 Revenue Estimate 320K 410K 180K 110K Revenue A
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.150) by 1.74 percent. The company reported quarterly sales of $826.000 thousand which beat the analyst consensus estimate of $1.750 thousand by 47.10K percent. This is a 61.33 percent increase over sales of $512.000 thousand the same period last year.
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, End
AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. After a distinguished 40-year career as an accountant and financial executive, including over 15 successful years with the Company and its predecessor, Chief Financial Officer Carl Langren has announced his plans to retire effective as of July 4, 2021. Mr. Langren has served as CFO of the Company since November 2018. After his departure, Mr. Langren will continue to serve as a consultant to Lumos Pharma for a
Data published in the Journal of Endocrine Society and accepted for presentation at ENDO 2021 demonstrate distinct mechanism of action and potential efficacy of LUM-201 in subset of pediatric growth hormone deficiency (PGHD) patientsFinal tranche of $26 million non-dilutive funds from PRV sale received in January 2021 AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2020 and provided an update on clinical activities and financial guidance for 2021. “The fourth quarter and full year 2020 were marked by signific
AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson brings over 30 years of experience in executive and clinical development roles in the pharmaceutical industry. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his Board position to focus on other professional obligations in his managerial role at Blackstone Life Sciences. “We are excited to welcome D